Table 2.
The relative reduction (%) of observed number of NIDs during weeks 4–53 compared with the expected in Guangdong Province of China in 2020
| Notifiable infectious diseases | Weeks 4–53 (95% CI) | Weeks 4–8 (95% CI) | Weeks 9–19 (95% CI) | Weeks 20–53 (95% CI) |
|---|---|---|---|---|
| Overall | 65·6 (64·0– 68·2) | 57·9 (50·9– 66·1) | 71·8 (68·7 – 75·8) | 64·6 (62·6 – 67·9) |
| Gender | ||||
| Male | 64·0 (61·6 – 67·5) | 58·1 (48·2 – 68·1) | 69·8 (65·3 – 75·3) | 62·9 (60·0 – 67·2) |
| Female | 68·0 (65·6 – 71·6) | 57·6 (46·5 – 69·1) | 74·6 (70·4 – 79·9) | 67·1 (64·2 – 71·5) |
| Age group | ||||
| Children (0–14 years) | 82·1 (80·4 – 84·9) | 62·4 (50·0 – 76·0) | 89·5 (87·3 – 92·4) | 81·8 (79·8 – 85·1) |
| Adults (15–64 years) | 38·2 (35·3 – 42·0) | 51·5 (43·7 – 59·6) | 49·2 (43·7 – 55·4) | 32·6 (28·6 – 37·6) |
| The elderly (65- years) | 26·2 (23·1 – 30·2) | 46·0 (38·1 – 54·4) | 35·3 (29·2 – 42·3) | 20·5 (16·4 – 25·6) |
| Intestinal infectious disease | 59·4 (56·3 – 66·4) | 68·4 (60·5 – 77·2) | 75·2 (70·8 – 82·0) | 55·0 (50·7 – 64·2) |
| Hand-foot-and-mouth disease | 76·2 (73·0 – 82·4) | 75·7 (65·5 – 87·0) | 96·5 (95·1 – 98·0) | 73·1 (69·0 – 80·6) |
| Infectious diarrhea* | 37·5 (32·8 – 44·8) | 68·4 (59·9 – 77·6) | 58·5 (51·3 – 67·9) | 21·7 (14·5 – 32·0) |
| Acute hemorrhagic conjunctivitis | 47·4 (44·2 – 52·1) | 35·6 (21·6 – 51·1) | 57·9 (52·2 – 64·7) | 45·2 (41·1 – 51·0) |
| Others | 21·5 (17·3 – 27·4) | 23·3 (9·0 – 38·0) | 31·4 (23·3 – 41·3) | 18·6 (13·1 – 25·9) |
| Respiratory infectious disease | 87·4 (85·6 – 93·1) | 71·4 (56·4 – 91·6) | 92·7 (90·5 – 97·2) | 86·8 (84·5 – 93·6) |
| Influenza | 95·1 (94·3 – 97·4) | 76·1 (61·3 – 93·5) | 98·0 (97·3 – 99·3) | 96·4 (95·6 – 98·4) |
| Pulmonary tuberculosis | 6·4 (3·2 – 10·1) | 18·7 (10·0 – 27·8) | 13·5 (7·3 – 20·3) | 1·8 (-2·2 – 6·5) |
| Mumps | 51·8 (49·7 – 54·5) | 43·2 (35·3 – 51·7) | 67·8 (64·8 – 71·2) | 48·0 (45·2 – 51·5) |
| Scarlet Fever | 86·0 (84·6 – 88·7) | 84·7 (79·6 – 89·8) | 93·7 (92·4 – 95·4) | 82·2 (79·7 – 86·6) |
| Pertussis | 90·3 (89·5 – 91·9) | 55·8 (41·2 – 71·2) | 85·5 (82·6 – 89·5) | 94·9 (94·3 – 95·9) |
| Others | 85·2 (83·3 – 88·9) | 75·8 (66·7 – 85·3) | 92·6 (90·8 – 95·3) | 82·2 (79·3 – 87·8) |
| Natural focal diseases and insect-borne infectious diseases | 89·4 (87·2 – 94·1) | 59·7 (50·0 – 77·5) | 55·6 (49·5 – 68·9) | 91·9 (90·1 – 95·7) |
| Dengue fever | 99·3 (99·1 – 99·6) | 91·7 (86·5 – 97·0) | 97·2 (96·2 – 98·7) | 99·4 (99·3 – 99·7) |
| HFRS | 36·0 (28·6 – 48·6) | 65·7 (50·0 – 80·0) | 45·3 (31·9 – 62·7) | 23·2 (11·7 – 40·8) |
| Human brucellosis | 18·9 (9·7 – 34·7) | 21·9 (-13·6 – 54·5) | 30·3 (13·8 – 52·0) | 11·3 (-1·5 – 31·8) |
| Others | -9·9 (-22·4 – 10·9) | 5·9 (-33·3– 48·4) | 28·9 (8·6 – 52·9) | -19·9 (-36·0 – 6·3) |
| Blood-borne and sexually transmitted infections | 18·2 (16·0 – 21·0) | 45·4 (40·6 – 50·8) | 27·9 (23·6 – 32·8) | 12·5 (9·7 – 16·2) |
| Syphilis | 14·6 (7·4 – 26·9) | 47·3 (30·0 – 65·6) | 26·3 (12·3 – 45·4) | 8·6 (-0·8 – 24) |
| Gonorrhea | 15·4 (12·0 – 19·5) | 53·8 (47·9 – 59·8) | 40·4 (35·5 – 45·9) | 4·7 (0 – 10·3) |
| AIDS | 19·7 (16·7 – 23·4) | 41·5 (34·3 – 49·1) | 22·9 (16·5 – 29·7) | 16·5 (12·8 – 21·2) |
| Other infectious diseases | 8·5 (5·8 – 11·9) | 40·1 (34·1 – 46·4) | 19·7 (14·5 – 25·7) | 0·6 (-3·1– 5·0) |
| Hepatitis B | 7·8 (4·5 – 11·8) | 40·1 (32·8 – 47·4) | 19·1 (12·7 – 26·3) | -0·2 (-4·6 – 5·1) |
| Other hepatitis# and neonatal tetanus | 11·7 (8·5 – 15·5) | 40·3 (33·2 – 47·4) | 22·4 (16·3 – 29·1) | 4·2 (0 – 9·1) |
⁎
Infectious diarrhea here does not include cholera, dysentery, typhoid and paratyphoid fever.
#
Other hepatitis includes hepatitis A, hepatitis C, hepatitis D, hepatitis E, and unidentified hepatitis. HFRS Hemorrhagic fever with renal syndrome. AIDS: Acquired immune deficiency syndrome Relative reduction (%) = 100% × (number of expected cases – number of observed cases)/number of expected cases.